Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CCR9 | P51686 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.46 |
| ▸ | TUBB | P07437 | 1/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8483054 | 0.89 | MAPT (0.67) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL24149128 | 0.84 | MAPT (0.65) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL9726394 | 0.84 | MAPT (0.58) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL25653103 | 0.84 | CES2 (0.53) | MAPTRAB9AKMT2AMEN1LMNA | |
| SCHEMBL17941 | 0.84 | MAPT (0.52) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL4676500 | 0.83 | MAPT (0.63) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL8588323 | 0.83 | MAPT (0.70) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL181455 | 0.83 | MAPT (0.63) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL4679518 | 0.83 | MAPT (0.63) | MAPTNPSR1RAB9AKMT2AMEN1 | |
| SCHEMBL1457144 | 0.83 | KMT2A (0.63) | MAPTNPSR1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| US-7847074-B2 | Processes for preparing of glucopyranosyl-substituted (ethynyl-benzyl)-benzene derivatives and intermediates thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-07 | — | — | US | disclosed |
| EP-1924571-B1 | GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZENE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INT (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7687469-B2 | Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| US-7683160-B2 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7683160-B2 | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-23 | — | — | US | disclosed |
| US-7662790-B2 | Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-16 | — | — | US | disclosed |
| US-6936590-B2 | C-aryl glucoside SGLT2 inhibitors and method | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1224195-B1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2005-05-18 | — | — | EP | disclosed |
| US-6774112-B2 | ANTIDIABETIC AGENTS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-10 | — | — | US | disclosed |
| EP-1385856-A2 | AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD | Bristol-Myers Squibb Company (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | ASTRAZENECA AB (SE) | 2003-06-19 | — | — | US | disclosed |
| US-20030064935-A1 | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | ASTRAZENECA AB (SE) | 2003-04-03 | — | — | US | disclosed |
| WO-2002083066-A2 | AMINO ACID COMPLEXES OF C-ARYL GLUCOSIDES FOR TREATMENT OF DIABETES AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-24 | — | — | WO | disclosed |
| EP-1224195-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6414126-B1 | ANTIDIABETIC, ANTIOBESITY, ANTILIPEMIC, ANTIATHEROSCLEROTIC, ANTICOAGULANT, AND HYPOTENSIVE AGENTS; MARKUSH ENCOMPASSING DAPAGLIFOZIN AND DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| WO-2001027128-A1 | C-ARYL GLUCOSIDE SGLT2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114390-A1 | C-aryl glucoside SGLT2 inhibitors and method | SLC5A2, SLC5A1, UGGT1 | MAPT 1540/4885NPSR1 2753/4885RAB9A 3664/4885 |
| US-20030064935-A1 | Amino acid complexes of C-aryl glucosides for treatment of diabetes and method | SLC5A2, SLC5A1, OGFR | MAPT 2980/4885NPSR1 1753/4885RAB9A 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.